Sunitinib in the Treatment of Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm: A Multicenter Retrospective Study in China

#1439

Introduction: Sunitinib has shown activity against pancreatic neuroendocrine tumors(NEN) in a global phase III clinical trial.

Aim(s): To determine the efficacy and safety of sunitinib in the treatment of advanced gastroenteropancreatic NEN(GEP-NEN),and the clinical significance of steady-state sunitinib serum concentrations in China.

Materials and methods: We conducted a multicenter retrospective study including six centers from across China.A total of 50 patients with advanced GEP-NENs treated with sunitinib were evaluated.Steady-state serum concentrations of sunitinib were measured.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Jie C

Authors: Yuhong W, Huangying T, Kaizhou J, Qiuchen Y, Jie L,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, sunitinib, treatment,